Angiotensin II type 1 receptor blockers

Circulation

Volumn 103, Issue 6, 2001, Pages 904-912

  Burnier, M ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Angiotensin; Antihypertensive agents; Heart failure; Hypertension

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR; CANDESARTAN; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE; EPROSARTAN; IRBESARTAN; LOSARTAN; TELMISARTAN; VALSARTAN;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERANCE; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 0035852724     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.6.904     Document Type: Review

References (121)

1. Acute renal failure, tubular necrosis and myocardial infarction induced in the rabbit by intravenous angiotensin II
2. Essential hypertension: Renin and aldosterone, heart attack and stroke
3. Hypertension of renal origin: Evidence for two different mechanisms
4. Angiotensin-sodium interaction in blood pressure maintenance of renal hypertensive and normotensive rats
5. 8-angiotensin II for understanding and treatment of high blood pressure
6. Hypertension in man, exposure of the renin and sodium components using angiotensin II blockade
7. Reciprocal relation between renin dependency and sodium dependency in essential hypertension
8. Angiotensin II inhibition: Treatment of congestive cardiac failure in a high-renin hypertension
9. Congestive heart failure in normotensive man: Hemodynamics, renin and angiotensin II blockade
10. A specific orally active inhibitor of angiotensin-converting enzyme in man
11. Antihypertensive effect of the oral angiotensin converting enzyme inhibitor SQ 14225 in man
12. Inappropriate renin secretion in hypertension of chronic renal failure unmasked by captopril (SQ 14,225)
13. Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients
14. Improvement of chronic congestive heart failure by oral captopril
15. Central and peripheral hemodynamic effects of angiotensin inhibition in patients with refractory congestive heart failure
16. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
17. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
18. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients
19. Angiotensin II receptors and angiotensin II receptor antagonists
20. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: Physiological and pharmacological implications
21. Identification of a highly specific chymase as the major angiotensin-forming enzyme in the human heart
22. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors
23. Plasma bradykinin in angio-oedema
24. Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril
25. Converting enzyme inhibition in kinin-deficient brown Norway rats
26. 2 bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril
27. 2 receptor antagonism on the hypotensive effects of ACE inhibition
28. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects
29. Cloning and characterization of a human angiotensin II type 1 receptor
30. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition
31. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors
32. Angiotensin type 2 receptors are re-expressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism
33. Role of angiotensin subtype 2 receptor in neointima formation after vascular injury
34. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction
35. Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia
36. Angiotensin II type 1a receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction
37. 1 receptor: Gain-of-function study using gene transfer
38. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells
39. 2 receptor inhibits proliferation and promotes differentiation in PC12W cells
40. Effect of AT2 receptor blockade on the pathogenesis of renal fibrosis
41. Effects of AT1 and AT2 angiotensin receptor antagonists in angiotensin II-infused rats
42. Role of angiotensin receptor subtypes in mesenteric vascular proliferation and hypertrophy
43. The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3′, 5′-monophosphate and AT1 receptor -mediated prostaglandin E2 production in conscious rats
44. Nonpeptide angiotensin II receptor antagonists: The next generation in antihypertensive therapy
45. 1 receptor-transfected Chinese hamster ovary cells
46. 1 receptor antagonists: The role of tight antagonist binding
47. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II
48. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist
49. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects
50. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers
51. Dose-related efficacy of irbesartan for hypertension: An integrated analysis
52. Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations
53. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension
54. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension
55. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin converting enzyme inhibitors for the treatment of systemic hypertension
56. Blood pressure effects of the angiotensin II receptor blocker, losartan
57. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension
58. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension
59. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension
60. Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension
61. The efficacy and safety of valsartan compared with placebo in the treatment of essential hypertension
62. Valsartan, a new angiotensin II antagonist: Antihypertensive effects over 24 hours
63. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine
64. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy and safety compared with placebo and enalapril
65. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril
66. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy and safety compared to hydrochlorothiazide
67. Valsartan: Long term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension
68. Valsartan and atenolol in patients with severe primary hypertension
69. 24-Hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring: Irbesartan Multicenter Investigators' Group
70. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension
71. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension: Irbesartan Multicenter Investigators
72. A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension
73. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension
74. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect
75. Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension
76. Combination therapy with candesartan cilexetil plus hydrochlorothiazide in patients unresponsive to low-dose hydrochlorothiazide
77. Once-daily telmisartan compared with enalapril in the treatment of hypertension
78. The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension
79. Dose response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension
80. Clinical efficacy of eprosartan
81. Comparative safety and tolerability of angiotensin II receptor antagonists
82. Effects of modulators of the renin-angiotensin-aldosterone system on cough
83. Valsartan, a new angiotensin II receptor antagonist: A double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide
84. The incidence of cough: A comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist
85. Angioneurotic edema attributed to the use of losartan
86. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis
87. Losartan versus ramipril in the treatment of postrenal transplant erythrocytosis
88. Pilot study of the uricosuric effect of DuP 753, a new angiotensin II receptor antagonist, in healthy subjects
89. Salt-dependent renal effects of angiotensin II antagonist in healthy subjects
90. Renal effects of angiotensin II receptor blockade in normotensive subjects
91. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan In The Elderly study, ELITE)
92. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects
93. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?
94. 1 antagonist irbesartan vs enalapril in hypertensive patients
95. ACE inhibition and AngII receptor blockade improve glomerular size-selectivity in IgA nephropathy
96. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension
97. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin
98. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass
99. Prevention of renal injury in diabetic MWF rats by angiotensin II antagonism
100. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension
101. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure
102. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe heart failure
103. Losartan in heart failure: Hemodynamic effects and tolerability
104. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure
105. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to an angiotensin converting enzyme inhibitor therapy in patients with heart failure: Vasodilator Heart Failure Trial (V-HeFT) study group
106. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial: The Losartan Heart Failure Survival Study ELITE II
107. 1 receptor antagonists
108. Angiotensin II antagonists for hypertension: Are there differences in efficacy?
109. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension
110. Comparative efficacy of losartan and valsartan in mild-to-moderate hypertension: Results of 24-hour ambulatory blood pressure monitoring
111. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan
112. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension
113. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers irbesartan and losartan
114. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension
115. 1 receptor blockers in hypertension and heart failure: Clinical experience and future directions
116. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives
117. Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation
118. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy
119. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy
120. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study
121. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure